查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965793

光遺傳學致動器和感測器市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、疾病類型、地區和競爭格局分類，2021-2031年

Optogenetics Actuators and Sensors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球光遺傳學致動器和感測器市場預計將從 2025 年的 12.1 億美元成長到 2031 年的 17.1 億美元，複合年成長率達到 5.93%。

該領域包括生物儀器，使科學家能夠利用光精確控制和觀察神經功能。致動器利用光敏蛋白來影響神經細胞的放電，而感測器則利用螢光標記物來即時視覺化細胞訊號。推動這一領域發展的主要動力是神經系統疾病發病率上升帶來的日益沉重的負擔，這使得人們更需要先進的腦迴路分析技術來開發新的治療方法。例如，根據阿茲海默症協會估計，到2025年，約有720萬65歲及以上的美國人將患有老年失智症失智症，凸顯了利用這些研究技術加速藥物研發的緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 12.1億美元
市場規模：2031年 17.1億美元
複合年成長率：2026-2031年 5.93%
成長最快的細分市場 致動器
最大的市場 北美洲

另一方面，這些系統固有的複雜技術規範和高昂實施成本構成了巨大的市場障礙。實施這些先進工具需要昂貴的光學設備和分子生物學專業知識，這實際上限制了它們的使用，使其僅限於資金雄厚的學術機構和專業研究設施。除了這些高進入門檻之外，目前顱內光照射的侵入性要求也限制了其在臨床環境中的廣泛應用，使得大部分市場成長局限於臨床前研究領域。

市場促進因素

生技公司與學術機構之間的策略合作，以及大量的私人投資，是推動光遺傳學解決方案發展的主要動力。這些合作對於將理論分子生物學轉化為實際臨床應用至關重要，尤其是在退化性視網膜疾病的視力恢復領域。合作研究可以顯著降低病毒載體設計和臨床試驗的高成本。例如，2024年1月，Kiora Pharmaceuticals宣布與Thea Open Innovation達成一項價值高達3.01億美元的策略協議，旨在推進用於治療遺傳性視網膜疾病的小分子光開關的研發。這標誌著該行業從學術研究向商業化治療的重大轉變。

此外，全球神經系統疾病發病率的上升推動了對能夠調節特定腦迴路的精確致動器的需求日益成長。由於傳統藥物通常缺乏必要的空間解析度，針對與癲癇等疾病相關的特定神經通路的光遺傳學干預變得愈發迫切。根據世界衛生組織（WHO）2024年3月的報告，目前全球有超過34億人患有神經系統疾病，因此開發新的治療方法迫在眉睫。這種需求正在推動大量的資本投資；例如，Beacon Therapeutics在2024年完成了1.7億美元的B輪資金籌措，以加速眼科基因療法的研發。這反映了對尖端醫療技術的強勁資金支持。

市場挑戰

光遺傳學的廣泛應用主要受其複雜的技術要求和高昂的實施成本限制。利用這些先進工具需要對專用光學基礎設施進行大量投資，包括精密雷射、光纖介面和高速記錄設備。此外，有效操作這些儀器需要光學工程和分子生物學的專業知識，而這類技能稀少且取得成本極高。高昂的基礎設施成本和對專業人員的需求使得市場主要局限於頂尖學術機構，難以滲透到小規模實驗室和臨床環境。

對外部研究津貼的嚴重依賴加劇了這一障礙，使得研究人員極易受到經費削減的影響。高昂的設備購買成本意味著，科學界的財政緊縮會立即限制採購活動。例如，2024年，神經科學學會指出，聯邦政府對「腦計畫」（舉措）的撥款——該計畫是神經技術設備購置的關鍵資金來源——被削減至4.02億美元。這項大幅削減嚴重限制了可用於購買先進實驗設備的資金。此類預算限制迫使實驗室推遲或放棄購置必要的感測器和致動器，直接阻礙了市場成長。

市場趨勢

視網膜色素變性光遺傳治療方法的臨床進展標誌著從理論神經科學到實際恢復人類視力的重大轉變。這一趨勢的標誌是，不依賴突變的視蛋白成功進入後期臨床試驗階段，證明光敏蛋白可以重新運作嚴重視力障礙患者的視網膜迴路。現代療法正擺脫對複雜外部硬體的依賴，轉而專注於在環境光下工作的高靈敏度致動器。 2024年10月，Nanoscope Therapeutics公司報告稱，一項MCO-010療法的隨機試驗顯示，患者的最佳矯正視力得到了具有統計學意義的顯著改善（約0.3 LogMAR），證實了該療法在恢復功能性視力方面的有效性。

同時，利用微型LED陣列實現的光傳輸系統小型化正在革新神經刺激技術，使其能夠實現高解析度的植入式介面。這項技術突破克服了傳統光纖連接的局限性，將超高密度光源嵌入可適應生物組織的軟性薄膜基板上。這些混合設備將基因療法與先進工程技術相結合，能夠以極高的空間精度靶向特定的神經層。為了佐證這項進展，Science Corporation於2024年4月宣布將收購Pixium的視網膜植入技術，以增強其Science Eye設備。 Science Eye設備獨特地將光遺傳學基因療法與可植入的軟性微型LED顯示器結合，從而直接刺激視網膜神經節細胞。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球光遺傳學致動器和感測器市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按產品（致動器、感測器）
    • 疾病類型（視網膜疾病、帕金森氏症、焦慮/憂鬱症、自閉症、思覺失調症、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美光遺傳學致動器和感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲光遺傳學致動器和感測器的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區光遺傳學致動器和感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲光遺傳學致動器和感測器的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美光遺傳學致動器和感測器的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球光遺傳學致動器和感測器市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Inscopix
  • Thorlabs
  • Hamamatsu
  • NeuroNexus
  • OptoGenTech
  • Boston Micromachines
  • Nanoscribe
  • Cyrus Biosystems
  • Blueberry Therapeutics
  • Neurolight

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25406

The Global Optogenetics Actuators & Sensors Market is projected to expand from USD 1.21 Billion in 2025 to USD 1.71 Billion by 2031, achieving a compound annual growth rate of 5.93%. This sector encompasses biological instruments that allow scientists to precisely regulate and observe neural functions via light; actuators utilize photosensitive proteins to influence neuronal firing, while sensors employ fluorescent markers to image cellular signals in real time. A key factor propelling this growth is the increasing burden of neurological conditions, which fuels the need for sophisticated brain circuitry analysis to identify novel therapeutic avenues. For instance, the Alzheimer's Association estimates that in 2025, approximately 7.2 million Americans aged 65 or older will have Alzheimer's dementia, highlighting the urgent need for these investigative technologies to expedite drug discovery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.21 Billion
Market Size 2031USD 1.71 Billion
CAGR 2026-20315.93%
Fastest Growing SegmentActuators
Largest MarketNorth America

Conversely, the market faces significant hurdles due to the complex technical specifications and substantial implementation costs inherent to these systems. Deploying these advanced tools necessitates costly optical equipment and specialized knowledge in molecular biology, effectively limiting their use to adequately funded academic centers and specialized research facilities. This high barrier to entry, combined with the invasive requirement for intracranial light delivery, currently restricts broad clinical adoption and confines the majority of market growth to preclinical research environments.

Market Driver

Strategic partnerships between biotechnology companies and academic institutions, supported by significant private investment, serve as a major engine for the progress of optogenetic solutions. These alliances are crucial for converting theoretical molecular biology into practical clinical applications, especially regarding vision restoration for degenerative retinal conditions. Collaborative efforts allow entities to mitigate the substantial expenses linked to viral vector engineering and clinical testing. To illustrate, Kiora Pharmaceuticals announced in January 2024 that it entered a strategic agreement with Thea Open Innovation, valued at up to $301 million, to advance a small molecule photoswitch for treating inherited retinal diseases, marking a decisive industry move from academic research to commercial therapeutics.

Additionally, the escalating global incidence of neurological disorders drives the demand for precise actuators capable of modulating specific brain circuits. Because traditional pharmaceuticals often lack necessary spatial resolution, there is a pressing need for optogenetic interventions that target distinct neural pathways associated with diseases like epilepsy. According to a March 2024 World Health Organization release, neurological conditions now affect over 3.4 billion individuals globally, establishing a critical requirement for novel treatment modalities. This demand has triggered substantial capital investment; for example, Beacon Therapeutics secured $170 million in Series B financing in 2024 to speed up ophthalmic gene therapy development, reflecting the strong financial backing for these cutting-edge medical technologies.

Market Challenge

The widespread adoption of optogenetics is severely hindered by the intricate technical demands and prohibitive costs associated with implementing these systems. Utilizing such sophisticated tools requires substantial investment in specialized optical infrastructure, including precision lasers, fiber-optic interfaces, and high-speed recording equipment. Moreover, operating this machinery effectively calls for advanced expertise in both optical engineering and molecular biology, a skill set that is both rare and expensive to secure. This combination of high infrastructure costs and the need for specialized personnel largely confines the market to elite academic institutions, preventing deeper penetration into smaller labs and clinical environments.

This obstacle is further aggravated by the market's strong dependence on external research grants, rendering it highly vulnerable to reductions in funding availability. The substantial cost of ownership implies that fiscal tightening within the scientific community immediately restricts procurement activities. For instance, the Society for Neuroscience noted in 2024 that federal funding for the BRAIN Initiative-a vital source for acquiring neurotechnology-was slashed to $402 million, a sharp reduction that significantly limited the funds available for purchasing advanced experimental tools. Such budgetary constraints directly hamper market growth by compelling laboratories to postpone or abandon the acquisition of necessary sensors and actuators.

Market Trends

The clinical advancement of optogenetic therapies for Retinitis Pigmentosa marks a pivotal shift from theoretical neuroscience to the tangible restoration of human vision. This trend is defined by the successful progression of mutation-agnostic opsins into late-stage clinical trials, proving that light-sensitive proteins can reactivate retinal circuitry in individuals with profound vision loss. Modern approaches have moved beyond complex external hardware to favor high-sensitivity actuators that function under ambient light. In October 2024, Nanoscope Therapeutics reported that patients in their randomized trial for the MCO-010 therapy achieved a statistically significant improvement in best-corrected visual acuity of roughly 0.3 LogMAR, confirming the treatment's efficacy in restoring functional vision.

In parallel, the miniaturization of light delivery systems via micro-LED arrays is transforming neural stimulation by facilitating high-resolution, implantable interfaces. This technological leap resolves the constraints of traditional fiber-optic tethering by embedding ultra-dense light sources on flexible thin-film substrates that adapt to biological tissue. These hybrid devices merge gene therapy with advanced engineering to target specific neuronal layers with exceptional spatial precision. As evidence of this progress, Science Corporation announced in April 2024 the acquisition of Pixium's retinal implant technology to enhance its Science Eye device, which uniquely combines optogenetic gene therapy with an implanted flexible micro-LED display to directly stimulate retinal ganglion cells.

Key Market Players

  • Inscopix
  • Thorlabs
  • Hamamatsu
  • NeuroNexus
  • OptoGenTech
  • Boston Micromachines
  • Nanoscribe
  • Cyrus Biosystems
  • Blueberry Therapeutics
  • Neurolight

Report Scope

In this report, the Global Optogenetics Actuators & Sensors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optogenetics Actuators & Sensors Market, By Product

  • Actuators
  • Sensors

Optogenetics Actuators & Sensors Market, By Disease Type

  • Retinal Disorders
  • Parkinson's Disease
  • Anxiety & Depression
  • Autism
  • Schizophrenia
  • Others

Optogenetics Actuators & Sensors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optogenetics Actuators & Sensors Market.

Available Customizations:

Global Optogenetics Actuators & Sensors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optogenetics Actuators & Sensors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Actuators, Sensors)
    • 5.2.2. By Disease Type (Retinal Disorders, Parkinson's Disease, Anxiety & Depression, Autism, Schizophrenia, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Optogenetics Actuators & Sensors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Optogenetics Actuators & Sensors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Disease Type
    • 6.3.2. Canada Optogenetics Actuators & Sensors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Disease Type
    • 6.3.3. Mexico Optogenetics Actuators & Sensors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Disease Type

7. Europe Optogenetics Actuators & Sensors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Optogenetics Actuators & Sensors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Disease Type
    • 7.3.2. France Optogenetics Actuators & Sensors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Disease Type
    • 7.3.3. United Kingdom Optogenetics Actuators & Sensors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Disease Type
    • 7.3.4. Italy Optogenetics Actuators & Sensors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Disease Type
    • 7.3.5. Spain Optogenetics Actuators & Sensors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Disease Type

8. Asia Pacific Optogenetics Actuators & Sensors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Optogenetics Actuators & Sensors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Disease Type
    • 8.3.2. India Optogenetics Actuators & Sensors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Disease Type
    • 8.3.3. Japan Optogenetics Actuators & Sensors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Disease Type
    • 8.3.4. South Korea Optogenetics Actuators & Sensors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Disease Type
    • 8.3.5. Australia Optogenetics Actuators & Sensors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Disease Type

9. Middle East & Africa Optogenetics Actuators & Sensors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Optogenetics Actuators & Sensors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Disease Type
    • 9.3.2. UAE Optogenetics Actuators & Sensors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Disease Type
    • 9.3.3. South Africa Optogenetics Actuators & Sensors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Disease Type

10. South America Optogenetics Actuators & Sensors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Disease Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Optogenetics Actuators & Sensors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Disease Type
    • 10.3.2. Colombia Optogenetics Actuators & Sensors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Disease Type
    • 10.3.3. Argentina Optogenetics Actuators & Sensors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Disease Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Optogenetics Actuators & Sensors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Inscopix
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thorlabs
  • 15.3. Hamamatsu
  • 15.4. NeuroNexus
  • 15.5. OptoGenTech
  • 15.6. Boston Micromachines
  • 15.7. Nanoscribe
  • 15.8. Cyrus Biosystems
  • 15.9. Blueberry Therapeutics
  • 15.10. Neurolight

16. Strategic Recommendations

17. About Us & Disclaimer